Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 222-227

  Saito, Isao ^a   Yamagishi, Kazumasa ^b,e   Chei, Choy Lye ^b,c   Cui, Renzhe ^d   Ohira, Tetsuya ^d   Kitamura, Akihiko ^e   Kiyama, Masahiko ^e   Imano, Hironori ^d   Okada, Takeo ^e   Kato, Tadahiro ^f   Hitsumoto, Shinichi ^a   Ishikawa, Yoshinori ^e   Tanigawa, Takeshi ^a   Iso, Hiroyasu ^d  

^a Department of Medical Welfare Support Center ^*  (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Singapore Graduate Medical School   (Singapore)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Osaka Center for Cancer and Cardiovascular Diseases Prevention   (Japan)

^f EHIME UNIVERSITY   (Japan)

Author keywords

Adiponectin; Cardiovascular disease; Epidemiology; Prospective study

Indexed keywords

ADIPONECTIN; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; RISK ASSESSMENT;

ADIPONECTIN; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS;

EID: 84879421016     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.014     Document Type: Article

References (40)

1. Pajvani U.B., Du X., Combs T.P., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. JBiol Chem 2003, 278:9073-9085.
2. Waki H., Yamauchi T., Kamon J., et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. JBiol Chem 2003, 278:40352-40363.
3. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
4. Hara K., Horikoshi M., Yamauchi T., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
5. Szmitko P.E., Teoh H., Stewart D.J., Verma S. Adiponectin and cardiovascular disease: state of the art?. Am J Physiol Heart Circ Physiol 2007, 292:H1655-H1663.
6. Heidemann C., Sun Q., van Dam R.M., et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008, 149:307-316.
7. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
8. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
9. Lawlor D.A., Davey Smith G., Ebrahim S., Thompson C., Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. JClin Endocrinol Metab 2005, 90:5677-5683.
10. Ogorodnikova A.D., Wassertheil-Smoller S., Mancuso P., et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke 2010, 41:1376-1381.
11. Sattar N., Watt P., Cherry L., Ebrahim S., Davey Smith G., Lawlor D.A. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. JClin Endocrinol Metab 2008, 93:1846-1849.
12. Kizer J.R., Barzilay J.I., Kuller L.H., Gottdiener J.S. Adiponectin and risk of coronary heart disease in older men and women. JClin Endocrinol Metab 2008, 93:3357-3364.
13. Kanaya A.M., Wassel Fyr C., Vittinghoff E., et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. JClin Endocrinol Metab 2006, 91:5044-5050.
14. Wannamethee S.G., Whincup P.H., Lennon L., Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007, 167:1510-1517.
15. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
16. Saito I., Kokubo Y., Yamagishi K., Iso H., Inoue M., Tsugane S. Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis 2011, 216:187-191.
17. Cui R., Iso H., Yamagishi K., et al. Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan Public Health Center study. Stroke 2011, 42:2611-2614.
18. Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). JEpidemiol 2010, 20:185-191.
19. Saito I., Konishi M., Watanabe K., Kondo H., Fujimotos K., Okada K. The metabolic syndrome and risk of stroke in a rural community in Japan. Nippon Koshu Eisei Zasshi 2007, 54:677-683.
20. Iso H., Sato S., Kitamura A., et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 2007, 38:1744-1751.
21. Walker A.E., Robins M., Weinfeld F.D. The National survey of stroke. Clinical findings. Stroke 1981, 12:I13-I44.
22. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994, 90:583-612.
23. Nakamura M., Sato S., Shimamoto T. Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. JAtheroscler Thromb 2003, 10:145-153.
24. Ebinuma H., Miyazaki O., Yago H., Hara K., Yamauchi T., Kadowaki T. Anovel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 2006, 372:47-53.
25. Zou G. Amodified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
26. Hatano Y., Matsumoto M., Ishikawa S., Kajii E. Plasma adiponectin level and myocardial infarction: the JMS Cohort Study. JEpidemiol 2009, 19:49-55.
27. Matsumoto M., Ishikawa S., Kajii E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke 2008, 39:323-328.
28. Laughlin G.A., Barrett-Connor E., May S., Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165:164-174.
29. Spranger J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
30. Zhu N., Pankow J.S., Ballantyne C.M., et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. JClin Endocrinol Metab 2010, 95:5097-5104.
31. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. JBiol Chem 2004, 279:12152-12162.
32. Tonelli J., Li W., Kishore P., et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004, 53:1621-1629.
33. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
34. Teoh H., Strauss M.H., Szmitko P.E., Verma S. Adiponectin and myocardial infarction: a paradox or a paradigm?. Eur Heart J 2006, 27:2266-2268.
35. Kobayashi H., Ouchi N., Kihara S., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004, 94:e27-31.
36. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. JClin Endocrinol Metab 2008, 93:1489-1496.
37. Wannamethee S.G., Welsh P., Whincup P.H., et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?. Eur J Cardiovasc Prev Rehabil 2011, 18:65-71.
38. Isobe T., Saitoh S., Takagi S., et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005, 153:91-98.
39. INK4A signaling pathway. Diabetes 2010, 59:2949-2959.
40. Ceriello A., Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008, 25:1151-1156.